Antibody-Conjugated
ASO Development
Bridging the gap between genomic precision and targeted delivery. We engineer chimeric molecules that overcome biological barriers.
Redefining RNA Therapeutics
Antibody-Oligonucleotide Conjugates (AOCs) are the next frontier in precision medicine. While Antisense Oligonucleotides (ASOs) offer potent gene silencing, they struggle with cellular uptake and tissue specificity.
"By harnessing the targeting power of monoclonal antibodies, we hijack natural receptor-mediated pathways to deliver therapeutic payloads exactly where they are needed."
Our integrated platform solves the critical "drug delivery problem," enabling researchers to make breakthroughs in diseases affecting muscle, heart, and central nervous system tissues that were previously inaccessible..
Our Service Portfolio
End-to-end solutions designed to accelerate your therapeutic discovery, from antibody generation to manufacturing for preclinical drug development.
Custom AOC Development
Full-service conjugation of ASOs to mAbs, Fabs, or scFvs. We customize the drug-to-antibody ratio (DAR) to optimize potency and ensure stability.
Targeted Drug Delivery
Advanced delivery systems for Extra-Hepatic targets. We specialize in muscle (TfR1), CNS (BBB crossing), and tumor-specific delivery.
Antibody Selection
High-throughput screening of antibody libraries to identify candidates with rapid internalization rates and high specificity for conjugation.
Oligo Optimization
Chemical modification and linker design to enhance stability against nucleases and ensure intracellular release.
Preclinical Support
Bioanalytical testing, immunogenicity testing, and PK/PD studies for drug submissions that comply with regulatory guidelines.
Manufacturing
Seamless scale-up from milligram discovery batches to gram-scale pilot production with rigorous Quality Control.
Conjugation Technology
Precise chemical engineering strategies designed to maintain stability and maximize activity.
Chemical Methods
We employ site-specific conjugation technologies such as Cysteine re-bridging, Enzymatic labeling, and Click chemistry to control the Drug-to-Antibody Ratio (DAR) precisely and maintain antibody affinity.
Linker Design
Our library includes both cleavable (Val-Cit, disulfide) and non-cleavable linkers. We match the linker strategy to the target tissue's intracellular environment (pH, enzymes) to ensure optimal payload release.
Stability & Efficiency
Rigorous formulation development ensures the conjugate remains stable in plasma without aggregation, maximizing delivery efficiency to the target organ and minimizing renal clearance.
Research Focus Areas
We provide specialized AOC development solutions for therapeutics targeting diseases that are challenging to treat with conventional modalities.
Oncology
Solid tumors, Metastasis & Tumor Microenvironment.
Neurodegenerative
Alzheimer's, ALS & Crossing the Blood-Brain Barrier.
Muscular Dystrophy
DMD, Myotonic Dystrophy & Muscle targeting.
Rare Diseases
Orphan indications, Metabolic disorders & Enzyme defects.
Antibody Optimization
The vehicle determines the destination. We select antibodies not just for binding, but for their ability to carry the payload into the cell.
"Optimal internalization kinetics are as critical as binding affinity."
Strict Screening Parameters
-
Affinity Nanomolar binding to target antigen (Kd < 10nM).
-
Specificity Validated against a panel of 50+ normal tissue types.
-
Internalization >50% internalization within 2 hours of binding.
| Parameter | Naked ASO | Antibody-Conjugated ASO |
|---|---|---|
| Tissue Specificity | Low (Accumulates in Liver/Kidney) | High (Antigen-Driven) |
| Cellular Uptake | Inefficient (Relies on Gymnosis) | Active (Receptor-Mediated Endocytosis) |
| Therapeutic Index | Narrow | Broad (Lower Dose Required) |
| Systemic Half-Life | Short (Rapid Clearance) | Extended (Fc-Mediated Recycling) |
Our Distinctive Features
Dual-Expertise Platform
Most CROs specialize in either Biologics or Chemistry—rarely both. Creative Biolabs possesses deep in-house expertise in both Antibody Engineering and Oligonucleotide Chemistry. This allows us to optimize the entire molecule as a single functional unit, preventing the common "siloed" development issues.
Development Workflow
Consultation
Target definition, sequence selection & feasibility assessment.
Engineering
Antibody modification (Cys/Lys) & Oligo functionalization.
Conjugation
Precise chemical linking, purification & DAR analysis.
Validation
In vitro potency assays, uptake studies & stability testing.
Success Stories
Targeting Skeletal Muscle
Challenge: Naked ASO showed poor efficacy in DMD models due to lack of uptake.
Solution: Conjugated to anti-TfR1 antibody.
Result:
Crossing the Blood-Brain Barrier
Challenge: Achieving systemic delivery to the brain without invasive injection techniques.
Solution: Developed a BBB-shuttle bispecific antibody-ASO.
Result:
Why Partner with Creative Biolabs?
End-to-End Support
From antibody discovery to IND-enabling studies, we handle every step of the pipeline.
Proprietary Tech
Access to exclusive linkers and conjugation methods that ensure high yield and purity.
Flexibility
Modular project scopes to fit your budget, timeline, and specific scientific needs.
Frequently Asked Questions
- Binding: The antibody component binds specifically to a receptor on the surface of the target cell (e.g., Transferrin receptor for muscle/CNS targeting).
- Internalization: This binding triggers receptor-mediated endocytosis, pulling the conjugate into the cell.
- Release: Once inside the endosome, the linker connecting the antibody and ASO is cleaved (or the ASO escapes via other mechanisms), releasing the payload.
- Action: The free ASO traffics to the nucleus or cytoplasm, where it binds to its target mRNA to inhibit translation or modulate splicing, treating the disease at the genetic level.
- Tissue Specificity: It directs the drug to specific organs (e.g., heart, muscle) rather than accumulating in the liver and kidneys.
- Enhanced Potency: Active transport allows for higher intracellular concentrations of the drug.
- Lower Toxicity: Because less drug is required to achieve a therapeutic effect, systemic side effects are minimized.
- Bioavailability: Antibodies can facilitate crossing biological barriers, such as the Blood-Brain Barrier (BBB), which are typically impermeable to naked ASOs.
- Humanization: Reducing immunogenicity for clinical safety.
- Fc Silencing: Mutating the Fc region to prevent unwanted immune system activation (ADCC/CDC).
- Site-Specific Engineering: Introducing specific attachment points (like engineered Cysteines) to ensure a consistent Drug-to-Antibody Ratio (DAR) and product homogeneity.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
